Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AvePoint (AVPT) Research & Development (2020 - 2025)

AvePoint (AVPT) has disclosed Research & Development for 6 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 0.99% to $13.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $52.6 million, a 7.98% increase, with the full-year FY2025 number at $52.6 million, up 7.98% from a year prior.
  • Research & Development was $13.0 million for Q4 2025 at AvePoint, down from $13.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $19.6 million in Q3 2021 to a low of $3.9 million in Q2 2021.
  • A 5-year average of $10.1 million and a median of $9.3 million in 2023 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 108.11% in 2022; the steepest drop was 53.1% in 2022.
  • AvePoint's Research & Development stood at $4.5 million in 2021, then soared by 66.57% to $7.5 million in 2022, then increased by 25.3% to $9.4 million in 2023, then skyrocketed by 36.81% to $12.9 million in 2024, then rose by 0.99% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for AVPT's Research & Development are $13.0 million (Q4 2025), $13.9 million (Q3 2025), and $13.0 million (Q2 2025).